DESCRIPTION (provided by applicant): Actin is a highly abundant protein that has a conserved structure across many species. It occurs in a monomer and polymer form and is involved in cell motility, division, organelle transport and muscle contraction. Actin binds to adenosine triphosphate (ATP) and will also catalyze its hydrolysis to adenosine diphosphate (ADP). The rates for this reaction are greatly different for free actin monomers and polymerized actin monomers. Additionally, the state of this nucleotide - ATP, ADP, or ADP plus an inorganic phosphate - plays a critical role in the structure, function and dynamics of actin. Despite experimental and computational scrutiny, there remain many questions about the effect of the bound nucleotide on actin polymers as well as the mechanism of actin catalyzed-ATP hydrolysis. In addition to its role in actin function, the hydrolysis of ATP to ADP is also the main source of energy used to drive biological reactions. Due to its importance to biochemistry, the exact nature of the source of this energy in different environments (protein and solution) remains an area of active debate. Our knowledge in these areas can be improved through the development, application and eventual combination of two different molecular dynamics (MD) methods. The main benefit of MD simulations is that they contain the atomistic details of the problem of interest but they suffer from their inability to allow bonds to break and reform. However, a reactive MD simulation of ATP hydrolysis can be constructed via the proposed multistate molecular dynamics (MS-MD) methodology. MS-MD is a generalization of the multistate empirical valence bond (MS-EVB) theory, which has hitherto been mainly applied to proton solvation and transport in water and has been recently extended to amino acid protonation. However, atomistic MD is computationally expensive for large systems like polymerized actin. This bottleneck can be overcome if some or all of the actin polymer is treated with a simplified, coarse-grained (CG) model using the multiscale coarse-graining (MS-CG) scheme, which is derived from the interactions of the full, atomistic-scale model. The combination of MS-MD and MS-CG will allow for the first detailed, accurate, fully reactive MD simulations of the nucleotide related properties of actin including actin-catalyzed ATP hydrolysis.
Public Health Relevance Statement
Actin is a key protein involved in cell division. Thus, it has been utilized as a target for cancer drugs. Additionally, since actin is also a structural protein involved in muscle contraction, its mutations are linked to several genetic muscle myopathies. Thus, understanding the detailed behavior of actin can allow for a more rational design of drugs and preventative agents for the above actin related diseases.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
005421136
UEI
ZUE9HKT2CLC9
Project Start Date
01-February-2011
Project End Date
31-January-2014
Budget Start Date
01-February-2012
Budget End Date
31-January-2013
Project Funding Information for 2012
Total Funding
$49,214
Direct Costs
$49,214
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2012
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$49,214
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5F32AR060698-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F32AR060698-02
Patents
No Patents information available for 5F32AR060698-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F32AR060698-02
Clinical Studies
No Clinical Studies information available for 5F32AR060698-02
News and More
Related News Releases
No news release information available for 5F32AR060698-02
History
No Historical information available for 5F32AR060698-02
Similar Projects
No Similar Projects information available for 5F32AR060698-02